Thats why I invested in this stock. Not only does AMBS have those pipelines, but most importantly, they own the intellectual property and have the keys to the science behind the whole picture. I like that they are setting the foundation by licensing. The more licensees they have the more revenue they will have. Also, the licensees will increase exposure. The only thing that concerns me with stocks like this are buyouts early into the growth stages. I don't think the company will sell out because they understand the value of the assets and the markets that are hungry for the products. All I know is there are a lot of catalysts still outstanding, and if we get good news from the closing of the clinical data and revenue guidance in the next couple of weeks, this stock will not return to penny land.